Synonyms |
|
|
Clinical
Indications |
|
High
cell turnover in myeloma results in raised serum
concentrations of b2-microglobulin
(b2M)
and renal dysfunction will result in serum retention
contributing to higher levels. b2M
is the single most important prognostic indicator in the
management of myelomatosis and reflects tumour mass, growth
rate and renal function. It is particularly useful as a tumour
marker in Bence-Jones myeloma where a serum paraprotein is
absent.
|
Request Form |
|
Combined Pathology Blood form
(Yellow/Black)
|
Availability |
|
Analysed by
referral laboratory
if specific criteria met.
|
Specific
Criteria |
|
Monitoring
and management of myeloma. Usually requested by Consultant
Haematologists.
|
Turnaround
Time |
|
1 week
|
Specimen |
|
Serum
|
Volume |
|
2 ml
|
Container |
|
Yellow top (SST) tube
|
Lab.
Handling |
|
Aliquot and store at 4C
|
Causes
for Rejection |
|
Not meeting specific criteria for
analysis.
|
Reference
Range |
|
Adult
reference range: 1.2 - 2.4 mg/L
Levels below 4.0 mg/L at presentation reflect best prognosis,
whereas levels above 20.0 mg/L reflect worst prognosis.
|